Form 4 · Statement of Changes in Beneficial Ownership · Filed 2025-12-11
Afeyan Noubar Files Moderna (MRNA) Form 4 - December 11, 2025
Afeyan Noubar traded 47.7K MRNA shares worth $963.3K in this Form 4 filing, reported to the SEC on 2025-12-11.
- Insider
- Afeyan Noubar
- Issuer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Period
- 2025-12-11
- Accession
- 0001193125-25-318567
- Source
- Official filing on sec.gov ↗
Transactions (2)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Afeyan Noubar | 2025-12-11 | Buy | 23.9K | $10.90 | $260.0K | Indirect |
| Afeyan Noubar | 2025-12-11 | Sell | 23.9K | $29.48 | $703.3K | Indirect |
| Net change | 0 | −$443.3K | ||||
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Track MRNA insider activity
Get alerted when Moderna Inc. executives buy or sell their shares.